Guardant Health Financial Statements (GH)
|
|
|
|
Report date
|
|
|
02.03.2020 |
25.02.2021 |
24.02.2022 |
23.02.2023 |
22.02.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
214.4 |
286.7 |
373.7 |
449.5 |
563.9 |
|
692.3 |
|
Operating Income, bln rub |
|
|
-82.4 |
-255.0 |
-411.0 |
-544.4 |
-564.7 |
|
-515.1 |
|
EBITDA, bln rub |
? |
|
-54.9 |
-225.1 |
-359.6 |
-614.9 |
-433.3 |
|
-466.9 |
|
Net profit, bln rub |
? |
|
-67.9 |
-246.3 |
-384.8 |
-654.6 |
-479.4 |
|
-512.4 |
|
|
OCF, bln rub |
? |
|
-47.1 |
-103.9 |
-209.0 |
-309.5 |
-325.0 |
|
-254.1 |
|
CAPEX, bln rub |
? |
|
21.3 |
54.1 |
75.0 |
77.5 |
20.5 |
|
20.3 |
|
FCF, bln rub |
? |
|
-68.4 |
-158.0 |
-284.1 |
-386.9 |
-345.5 |
|
-274.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
21.2 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
-4.14% |
|
|
OPEX, bln rub |
|
|
226.0 |
449.1 |
661.7 |
837.6 |
901.6 |
|
1 076 |
|
Cost of production, bln rub |
|
|
70.7 |
92.5 |
122.9 |
156.3 |
227.1 |
|
293.3 |
|
R&D, bln rub |
|
|
86.3 |
149.9 |
263.2 |
373.8 |
367.2 |
|
344.1 |
|
Interest expenses, bln rub |
|
|
1.18 |
4.77 |
2.58 |
2.58 |
2.58 |
|
2.58 |
|
|
Assets, bln rub |
|
|
962.5 |
2 272 |
2 204 |
1 610 |
1 786 |
|
1 539 |
|
Net Assets, bln rub |
? |
|
798.4 |
1 298 |
645.0 |
60.2 |
158.7 |
|
-60.1 |
|
Debt, bln rub |
|
|
33.3 |
847.9 |
1 361 |
1 369 |
1 354 |
|
1 339 |
|
Cash, bln rub |
|
|
522.8 |
1 795 |
932.7 |
1 011 |
1 169 |
|
999.1 |
|
Net debt, bln rub |
|
|
-489.5 |
-947.0 |
428.1 |
358.1 |
185.1 |
|
340.3 |
|
|
Ordinary share price, rub |
|
|
78.1 |
128.9 |
100.0 |
27.2 |
27.1 |
|
26.9 |
|
Number of ordinary shares, mln |
|
|
90.6 |
97.5 |
101.3 |
102.2 |
112.0 |
|
123.1 |
|
|
Market cap, bln rub |
|
|
7 079 |
12 566 |
10 133 |
2 779 |
3 029 |
|
3 308 |
|
EV, bln rub |
? |
|
6 590 |
11 619 |
10 562 |
3 137 |
3 214 |
|
3 648 |
|
Book value, bln rub |
|
|
780 |
1 279 |
628 |
45 |
146 |
|
-71 |
|
|
EPS, rub |
? |
|
-0.75 |
-2.53 |
-3.80 |
-6.41 |
-4.28 |
|
-4.16 |
|
FCF/share, rub |
|
|
-0.76 |
-1.62 |
-2.80 |
-3.79 |
-3.08 |
|
-2.23 |
|
BV/share, rub |
|
|
8.61 |
13.1 |
6.19 |
0.44 |
1.31 |
|
-0.57 |
|
|
EBITDA margin, % |
? |
|
-25.6% |
-78.5% |
-96.2% |
-136.8% |
-76.8% |
|
-67.4% |
|
Net margin, % |
? |
|
-31.7% |
-85.9% |
-103.0% |
-145.6% |
-85.0% |
|
-74.0% |
|
FCF yield, % |
? |
|
-0.97% |
-1.26% |
-2.80% |
-13.9% |
-11.4% |
|
-8.29% |
|
ROE, % |
? |
|
-8.50% |
-19.0% |
-59.7% |
-1 088% |
-302.1% |
|
852.7% |
|
ROA, % |
? |
|
-7.05% |
-10.8% |
-17.5% |
-40.7% |
-26.8% |
|
-33.3% |
|
|
P/E |
? |
|
-104.3 |
-51.0 |
-26.3 |
-4.25 |
-6.32 |
|
-6.46 |
|
P/FCF |
|
|
-103.5 |
-79.5 |
-35.7 |
-7.18 |
-8.77 |
|
-12.1 |
|
P/S |
? |
|
33.0 |
43.8 |
27.1 |
6.18 |
5.37 |
|
4.78 |
|
P/BV |
? |
|
9.08 |
9.83 |
16.1 |
61.5 |
20.7 |
|
-46.8 |
|
EV/EBITDA |
? |
|
-120.0 |
-51.6 |
-29.4 |
-5.10 |
-7.42 |
|
-7.81 |
|
Debt/EBITDA |
|
|
8.91 |
4.21 |
-1.19 |
-0.58 |
-0.43 |
|
-0.73 |
|
|
R&D/CAPEX, % |
|
|
405.4% |
277.2% |
350.8% |
482.6% |
1 792% |
|
1 696% |
|
|
CAPEX/Revenue, % |
|
|
9.93% |
18.9% |
20.1% |
17.2% |
3.63% |
|
2.93% |
|
| Guardant Health shareholders |
